Michael Richard Dwyer Ashton
Chairman at Komix Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Susan Ringdal | F | - | 19 years | |
| Nina Henderson | F | 73 | 8 years | |
| John Castellani | M | 73 | 8 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gregory Todd Bosch | M | 61 | 8 years | |
| Charles Spicer | M | 59 | 6 years | |
| Samih Taleb Darwazah | M | 94 | 37 years | |
| Ronald L. Goode | M | 79 | 12 years | |
| Donald Clarke | M | 69 | 4 years | |
| Patrick Butler | M | 63 | 10 years | |
| Sandra N. Webb | M | 76 | 4 years | |
| Alister Hodges | M | - | 2 years | |
| Jim Walsh | M | 65 | 1 years | |
| Peter Larkin | M | 70 | 3 years | |
| David Kenneth Rowe-Ham | M | 89 | 9 years | |
| John D. Mills | M | 83 | 6 years | |
| Breffni Byrne | M | 78 | 11 years | |
| Robert Pickering | M | 64 | 9 years | |
| Stuart James | M | 74 | 4 years | |
| Pamela Kirby | M | 70 | 8 years | |
| Alex Martin Martin | M | 56 | 4 years | |
| Ayman Ahmed Sahli | M | 61 | 4 years | |
| Bryan Hotston | M | - | - | |
| Jochen Gann | M | 60 | 4 years | |
| Brooke Clarke | F | - | 5 years | |
| Peter Speirs | M | 45 | 12 years | |
| Geoff Koontz | M | - | 9 years | |
| Jason Grenfell-Gardner | M | 49 | 4 years | |
| James W. Sharpe | M | - |
Astralis Ltd.
 Astralis Ltd. BiotechnologyHealth Technology Astralis Ltd. research and develop drugs for the treatment of immune system disorders and skin diseases. The company's initial product is Psoraxine, a protein extract used for the treatment of the skin disease psoriasis. Psoraxine is a synthesized immuno-therapeutic agent, presented in liquid form and is packed in 0.5 mg ampules for intra-muscular injection. The company's second product is for the treatment of leishmaniasis. The company was founded on June 30, 2001 and is headquartered in Fairfield, NJ. | - |
| Christopher Wightman | M | 66 | 14 years | |
| Manuel Tarabay | M | - |
Astralis Ltd.
Astralis Ltd. BiotechnologyHealth Technology Astralis Ltd. research and develop drugs for the treatment of immune system disorders and skin diseases. The company's initial product is Psoraxine, a protein extract used for the treatment of the skin disease psoriasis. Psoraxine is a synthesized immuno-therapeutic agent, presented in liquid form and is packed in 0.5 mg ampules for intra-muscular injection. The company's second product is for the treatment of leishmaniasis. The company was founded on June 30, 2001 and is headquartered in Fairfield, NJ. | - |
| Kristen M. Kyriakou | F | - | 3 years | |
| Fabien Pictet | M | - |
Astralis Ltd.
Astralis Ltd. BiotechnologyHealth Technology Astralis Ltd. research and develop drugs for the treatment of immune system disorders and skin diseases. The company's initial product is Psoraxine, a protein extract used for the treatment of the skin disease psoriasis. Psoraxine is a synthesized immuno-therapeutic agent, presented in liquid form and is packed in 0.5 mg ampules for intra-muscular injection. The company's second product is for the treatment of leishmaniasis. The company was founded on June 30, 2001 and is headquartered in Fairfield, NJ. | 4 years |
| Steven M. Fulda | M | - |
Astralis Ltd.
Astralis Ltd. BiotechnologyHealth Technology Astralis Ltd. research and develop drugs for the treatment of immune system disorders and skin diseases. The company's initial product is Psoraxine, a protein extract used for the treatment of the skin disease psoriasis. Psoraxine is a synthesized immuno-therapeutic agent, presented in liquid form and is packed in 0.5 mg ampules for intra-muscular injection. The company's second product is for the treatment of leishmaniasis. The company was founded on June 30, 2001 and is headquartered in Fairfield, NJ. | 3 years |
| Danny Robert Hegglin | M | 62 | 4 years | |
| Michael Sapountzoglou | M | 63 | 7 years | |
| Samuel T. Barnett | M | - |
Astralis Ltd.
Astralis Ltd. BiotechnologyHealth Technology Astralis Ltd. research and develop drugs for the treatment of immune system disorders and skin diseases. The company's initial product is Psoraxine, a protein extract used for the treatment of the skin disease psoriasis. Psoraxine is a synthesized immuno-therapeutic agent, presented in liquid form and is packed in 0.5 mg ampules for intra-muscular injection. The company's second product is for the treatment of leishmaniasis. The company was founded on June 30, 2001 and is headquartered in Fairfield, NJ. | 3 years |
| Andrew Lancelot Vizard | M | 66 | 11 years | |
| Mihalis Sapountzoglou | M | 63 | 9 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 16 | 42.11% |
| United States | 15 | 39.47% |
| Australia | 7 | 18.42% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michael Richard Dwyer Ashton
- Personal Network
